US Patent Issued to Artax Biopharma on June 3 for "Chromene derivatives as inhibitors of TCR-Nck interaction" (Spanish, British, American Inventors)

ALEXANDRIA, Va., June 4 -- United States Patent no. 12,319,675, issued on June 3, was assigned to Artax Biopharma Inc. (Cambridge, Mass.).

"Chromene derivatives as inhibitors of TCR-Nck interaction" was invented by Julio Castro (Barcelona, Spain), Andres Gagete Mateos (Valencia, Spain), Peter J. Machin (London) and Christopher Loren Vandeusen (Hopkinton, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same."

The patent was filed on Sept. 21, 2023, under Application No. 18/471,594.

*For further information, including images, charts and tables, please visit: ht...